Published on 7/9/2021 in the Prospect News Structured Products Daily.
New Issue: HSBC sells $104,000 buffered accelerated market participation notes on biotech ETF
By Kiku Steinfeld
Chicago, July 9 – HSBC USA Inc. priced $104,000 of 0% buffered Accelerated Market Participation Securities due May 28, 2024 linked to the SPDR S&P Biotech ETF, according to a 424B2 filing with the Securities and Exchange Commission.
If the fund return is positive, the payout at maturity will be par plus 150% of the fund return, capped at par plus 23.6%.
Investors will receive par if the fund falls by 15% or less and will lose 1% for every 1% decline beyond the 15% buffer.
HSBC Securities USA Inc. is the agent.
Issuer: | HSBC USA Inc.
|
Issue: | Buffered Accelerated Market Participation Securities
|
Underlying fund: | SPDR S&P Biotech ETF
|
Amount: | $104,000
|
Maturity: | May 28, 2024
|
Coupon: | 0%
|
Price: | Par
|
Payout at maturity: | If fund return is positive, par plus 150% of fund return, capped at par plus 23.6%; par if fund declines by 15% or less; 1% loss for every 1% fund declines beyond 15% buffer
|
Initial index level: | $125.84
|
Buffer level: | 85% of initial level
|
Pricing date: | May 24
|
Settlement date: | May 27
|
Agent: | HSBC Securities (USA) Inc.
|
Fees: | 2.5%
|
Cusip: | 40438C6Z9
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.